Jay Backstrom, M.D., M.P.H., is a seasoned medical professional and executive who currently serves as the President and Chief Executive Officer at Scholar Rock Holding Corp. Dr. Backstrom has a robust background in the biopharmaceutical industry, with extensive experience in leading clinical development and bringing innovative therapies to market. Before joining Scholar Rock, he held significant leadership roles at various reputable companies, including serving as the Chief Medical Officer at Acceleron Pharma, where he played a pivotal role in advancing the company's therapeutic pipeline. At Scholar Rock, Dr. Backstrom has been instrumental in steering the company's strategic direction and fostering its growth in the development of innovative treatments for neuromuscular disorders and cancer. His leadership has been crucial in advancing Scholar Rock's lead product candidate, apitegromab, into clinical trials, demonstrating his commitment to translating scientific discoveries into meaningful patient outcomes. Under his guidance, Scholar Rock has solidified its position as a pioneer in the targeted protein degradation field, focusing on the TGF-beta superfamily of cell signaling proteins. Dr. Backstrom's educational background includes a Doctor of Medicine degree from the University of Minnesota and a Master of Public Health from the Harvard T.H. Chan School of Public Health. His dual expertise in medicine and public health has equipped him with a unique perspective on healthcare innovation and patient care. As the President and CEO of Scholar Rock, Dr. Backstrom continues to lead with a vision to transform the lives of patients through groundbreaking therapies, leveraging his deep industry knowledge and passion for medical advancement.